Sudeep Pharma Share Price
1099.40-7.80 (-0.70%)
+42.01% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
SUDEEPPHRMNSE
Sudeep Pharma Share Price
1099.40-7.80 (-0.70%)
+42.01% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | 24% | 14% | 28% |
| - | 39% | 41% | 26% |
| - | - | - | - |
| 33% | 34% | 35% | 25% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
SUDEEPPHRM
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,769.9 | ₹424202 Cr | 38.68 | 8.29 | 58.23 | ₹11479 Cr |
| 10,064 | ₹264141 Cr | 90.3 | 34.04 | 128.41 | ₹2568 Cr |
| 4,650 | ₹174402 Cr | 82.11 | 14.04 | 106.21 | ₹2163 Cr |
| 2,323 | ₹126811 Cr | 94.64 | 8.17 | 33.94 | ₹889 Cr |
| 1,240.6 | ₹123685 Cr | 27.41 | 9.42 | 62.53 | ₹5040 Cr |
| 1,368.3 | ₹111868 Cr | 39.95 | 11.08 | 59.2 | ₹4196 Cr |
| 1,396.9 | ₹111650 Cr | 38.54 | 10.86 | 52.6 | ₹3879 Cr |
| 2,475 | ₹102196 Cr | 45.57 | 17.23 | 76.26 | ₹1913 Cr |
| 1,694.5 | ₹96951 Cr | 26.11 | 17.95 | 96.84 | ₹3505 Cr |
| 2,015.9 | ₹91301 Cr | 16.51 | 30.95 | 154.35 | ₹5333 Cr |
| 1,099.4 | ₹12503 Cr | 66.39 | 4.56 | 18.19 | ₹173 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| ₹197 Cr | ₹158 Cr | ₹182 Cr | ₹172 Cr | ₹163 Cr | ₹125 Cr | ₹158 Cr | ₹116 Cr | ₹149 Cr |
| ₹6 Cr | ₹5 Cr | ₹6 Cr | ₹7 Cr | ₹10 Cr | ₹5 Cr | ₹4 Cr | ₹2 Cr | ₹2 Cr |
| ₹203 Cr | ₹164 Cr | ₹189 Cr | ₹179 Cr | ₹173 Cr | ₹130 Cr | ₹161 Cr | ₹118 Cr | ₹151 Cr |
| ₹129 Cr | ₹107 Cr | ₹124 Cr | ₹116 Cr | ₹111 Cr | ₹84 Cr | ₹102 Cr | ₹79 Cr | ₹88 Cr |
| ₹79 Cr | ₹60 Cr | ₹69 Cr | ₹67 Cr | ₹66 Cr | ₹49 Cr | ₹63 Cr | ₹42 Cr | ₹65 Cr |
| ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr |
| ₹71 Cr | ₹54 Cr | ₹63 Cr | ₹62 Cr | ₹60 Cr | ₹44 Cr | ₹58 Cr | ₹38 Cr | ₹62 Cr |
| ₹52 Cr | ₹41 Cr | ₹49 Cr | ₹48 Cr | ₹47 Cr | ₹31 Cr | ₹44 Cr | ₹29 Cr | ₹49 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — |
| ₹11 Cr | ₹12 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| ₹872 Cr | ₹481 Cr | ₹355 Cr | ₹222 Cr | ₹162 Cr | ₹113 Cr | ₹80 Cr |
| ₹872 Cr | ₹481 Cr | ₹355 Cr | ₹222 Cr | ₹162 Cr | ₹113 Cr | ₹80 Cr |
| ₹883 Cr | ₹493 Cr | ₹356 Cr | ₹223 Cr | ₹163 Cr | ₹114 Cr | ₹81 Cr |
| ₹15 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹34 Cr | ₹40 Cr | ₹11 Cr | ₹20 Cr | ₹28 Cr | ₹14 Cr | ₹8 Cr |
| ₹9 Cr | ₹6 Cr | ₹6 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
| ₹31 Cr | ₹2 Cr | ₹2 Cr | ₹54 L | ₹0 | ₹0 | ₹80,952 |
| ₹4 L | ₹2 Cr | ₹1 Cr | ₹38 L | ₹81 L | ₹1 Cr | ₹94 L |
| ₹74 Cr | ₹49 Cr | ₹20 Cr | ₹25 Cr | ₹33 Cr | ₹19 Cr | ₹13 Cr |
| — | — | — | — | — | — | — |
| ₹68 Cr | ₹60 Cr | ₹51 Cr | ₹38 Cr | ₹27 Cr | ₹18 Cr | ₹9 Cr |
| ₹29 Cr | ₹25 Cr | ₹25 Cr | ₹71 Cr | ₹1 Cr | ₹19 Cr | ₹10 Cr |
| ₹102 Cr | ₹86 Cr | ₹54 Cr | ₹52 Cr | ₹55 Cr | ₹17 Cr | ₹9 Cr |
| ₹2 Cr | ₹4 Cr | ₹7 Cr | ₹10 Cr | ₹63 Cr | ₹27 Cr | ₹9 Cr |
| ₹202 Cr | ₹175 Cr | ₹137 Cr | ₹171 Cr | ₹147 Cr | ₹80 Cr | ₹37 Cr |
| ₹1174 Cr | ₹717 Cr | ₹514 Cr | ₹420 Cr | ₹344 Cr | ₹213 Cr | ₹131 Cr |
| ₹0 | ₹10 L | ₹10 L | ₹10 L | ₹26 L | ₹26 L | ₹0 |
| ₹148 Cr | ₹135 Cr | ₹75 Cr | ₹82 Cr | ₹84 Cr | ₹31 Cr | ₹20 Cr |
| — | — | — | — | — | — | — |
| ₹378 Cr | ₹216 Cr | ₹197 Cr | ₹166 Cr | ₹157 Cr | ₹83 Cr | ₹72 Cr |
| ₹41 Cr | ₹27 Cr | ₹17 Cr | ₹8 Cr | ₹20 Cr | ₹16 Cr | ₹12 Cr |
| ₹337 Cr | ₹189 Cr | ₹180 Cr | ₹158 Cr | ₹137 Cr | ₹68 Cr | ₹60 Cr |
| ₹178 Cr | ₹88 Cr | ₹45 Cr | ₹26 Cr | ₹8 Cr | ₹24 Cr | ₹8 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹19 Cr | ₹6 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹19 Cr | ₹6 Cr |
| ₹13 Cr | ₹15 Cr | ₹13 Cr | ₹5 Cr | ₹2 Cr | ₹2 Cr | ₹79 L |
| ₹15 Cr | ₹33 L | ₹32 L | ₹27 L | ₹0 | ₹0 | ₹0 |
| ₹550 Cr | ₹293 Cr | ₹238 Cr | ₹190 Cr | ₹147 Cr | ₹113 Cr | ₹75 Cr |
| — | — | — | — | — | — | — |
| ₹0 | ₹14 L | ₹13 L | ₹3 Cr | ₹0 | ₹0 | ₹0 |
| ₹216 Cr | ₹129 Cr | ₹67 Cr | ₹71 Cr | ₹37 Cr | ₹17 Cr | ₹9 Cr |
| ₹228 Cr | ₹185 Cr | ₹145 Cr | ₹94 Cr | ₹107 Cr | ₹55 Cr | ₹30 Cr |
| ₹115 Cr | ₹52 Cr | ₹14 Cr | ₹10 Cr | ₹21 Cr | ₹12 Cr | ₹4 Cr |
| ₹10 Cr | ₹19 Cr | ₹6 Cr | ₹4 Cr | ₹50 L | ₹32 L | ₹2 Cr |
| ₹56 Cr | ₹39 Cr | ₹44 Cr | ₹48 Cr | ₹31 Cr | ₹15 Cr | ₹10 Cr |
| ₹624 Cr | ₹424 Cr | ₹275 Cr | ₹230 Cr | ₹197 Cr | ₹99 Cr | ₹56 Cr |
| ₹422 Cr | ₹249 Cr | ₹138 Cr | ₹59 Cr | ₹50 Cr | ₹20 Cr | ₹20 Cr |
| ₹1174 Cr | ₹717 Cr | ₹514 Cr | ₹420 Cr | ₹344 Cr | ₹213 Cr | ₹131 Cr |
| ₹78 | ₹50 | ₹2,527 | ₹1,585 | ₹1,159 | ₹810 | ₹574 |
| ₹78 | ₹50 | ₹37 | ₹23 | ₹17 | ₹12 | ₹8 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
| ₹228 Cr | ₹183 Cr | ₹175 Cr | ₹86 Cr | ₹69 Cr | ₹43 Cr | ₹25 Cr |
| ₹9 Cr | ₹15 Cr | ₹13 Cr | ₹18 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr |
| -₹112 Cr | -₹109 Cr | -₹78 Cr | -₹33 Cr | -₹59 Cr | -₹1 Cr | -₹13 Cr |
| ₹125 Cr | ₹89 Cr | ₹110 Cr | ₹71 Cr | ₹15 Cr | ₹46 Cr | ₹16 Cr |
| ₹70 Cr | ₹49 Cr | ₹66 Cr | ₹48 Cr | -₹3 Cr | ₹35 Cr | ₹10 Cr |
| -₹331 Cr | -₹79 Cr | -₹49 Cr | -₹50 Cr | -₹38 Cr | -₹40 Cr | -₹22 Cr |
| ₹247 Cr | ₹53 Cr | -₹13 Cr | -₹10 Cr | ₹51 Cr | ₹13 Cr | ₹12 Cr |
| -₹14 Cr | ₹23 Cr | ₹4 Cr | -₹11 Cr | ₹10 Cr | ₹8 Cr | -₹16 L |
| ₹37 Cr | ₹14 Cr | ₹10 Cr | ₹21 Cr | ₹12 Cr | ₹4 Cr | ₹4 Cr |
| ₹4 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹28 L | ₹16 L | ₹50,000 | ₹23 L | ₹0 | ₹0 | ₹0 |
| ₹27 Cr | ₹37 Cr | ₹14 Cr | ₹10 Cr | ₹21 Cr | ₹12 Cr | ₹4 Cr |
Fundamental Ratios
Consolidated
Standalone
No results found
Sudeep Pharma Share Price
1099.40-7.80 (-0.70%)
+42.01% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 2
Bearish signals: 3 out of 9 oscillators
RSI
52.74Neutral
STOCH %K
74.26Neutral
MACD Level(12,26)
-10.42Sell
Ultimate Oscillator
62.46Buy
Aroon Oscillator
-62.00Sell
BOP
-0.27Sell
CCI
65.99Neutral
Williams %R
-25.74Neutral
Momentum
87.20Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 8
Bearish signals: 1 out of 9 moving averages
EMA 9
1070.96Buy
SMA 9
1050.84Buy
EMA 21
1072.09Buy
SMA 21
1056.88Buy
EMA 50
1075.36Buy
SMA 50
1134.73Sell
EMA 200
846.20Buy
SMA 200
828.07Buy
WMA 20
1047.43Buy
Pivot
Pivot
Classic
Resistance 5
1340.17
Resistance 4
1277.87
Resistance 3
1215.57
Resistance 2
1153.27
Resistance 1
1130.23
Pivot
1090.97
Support 1
1067.93
Support 2
1028.67
Support 3
966.37
Support 4
904.07
Support 5
841.77
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Sudeep Pharma Share Price
1099.40-7.80 (-0.70%)
+42.01% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Mar 2024 |
|---|---|---|---|---|---|
| 76.15% | 76.15% | 76.15% | 76.15% | 76.15% | 44.65% |
| 2.93% | 1.81% | 1.55% | 1.67% | 1.54% | 0.00% |
| 6.63% | 10.18% | 11.92% | 11.92% | 10.66% | 0.00% |
| 7.43% | 5.47% | 6.19% | 5.67% | 3.44% | 0.00% |
| 6.86% | 6.39% | 4.19% | 4.59% | 8.21% | 55.35% |
Bulk & block deals
Name
Nuvama Crossover Opportunities Fund - Series Iii
Goldman Sachs Funds - Goldman Sachs India Equity Portfolio
Nuvama Crossover Opportunities Fund - Series Iiia
Goldman Sachs Funds - Goldman Sachs India Equity Portfolio
Nuvama Crossover Opportunities Fund - Series Iii
Sbi Mutual Fund
Nuvama Crossover Opportunities Fund - Series Iii
Nuvama Crossover Opportunities Fund - Series Iiia
Nuvama Crossover Opportunities Fund - Series Iiia
Nuvama Crossover Opportunities Fund - Series Iii
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 04 Aug 2026 | Sell | 52.20 Cr | ₹850 | 6.14 L | Block | 0.543709 | NSE |
| 04 Aug 2026 | Purchase | 100 Cr | ₹850 | 11.76 L | Bulk | 1.041599 | NSE |
| 04 Aug 2026 | Sell | 47.80 Cr | ₹850 | 5.62 L | Block | 0.49789 | NSE |
| 04 Aug 2026 | Purchase | 100 Cr | ₹850 | 11.76 L | Block | 1.041599 | NSE |
| 04 Aug 2026 | Sell | 52.20 Cr | ₹850 | 6.14 L | Bulk | 0.543709 | NSE |
| 24 Jul 2026 | Purchase | 160 Cr | ₹800 | 20 L | Block | 1.770717 | NSE |
| 24 Jul 2026 | Sell | 84.80 Cr | ₹800 | 10.60 L | Block | 0.93848 | NSE |
| 24 Jul 2026 | Sell | 75.20 Cr | ₹800 | 9.40 L | Bulk | 0.832237 | NSE |
| 24 Jul 2026 | Sell | 75.20 Cr | ₹800 | 9.40 L | Block | 0.832237 | NSE |
| 24 Jul 2026 | Sell | 84.80 Cr | ₹800 | 10.60 L | Bulk | 0.93848 | NSE |
Insider trading & SAST
Client name
Nuvama Crossover Opportunities Fund Series Iii & Others
Nuvama Crossover Opportunities Fund Series Iii
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11 Aug 2026 | Other | Acquisition | 8.4 | 8.4 | 0 | — | 94.51 L | 09 Jul 2024 - 27 Nov 2025 | Pref. Allotment | 94,51,295 | SAST | 29(2) | — |
| 11 Aug 2026 | Other | Disposal | 2.4 | 6 | 0 | — | 26.68 L | 15 Jun 2026 - 24 Jul 2026 | Market | 67,83,177 | SAST | 29(2) | — |
Sudeep Pharma Share Price
1099.40-7.80 (-0.70%)
+42.01% past 1 Year
Sudeep Pharma along with its subsidiary companies is engaged in business of manufacturing of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries and is dedicated to contributing
Corporate Actions
Date
Type
Details
Company details
Sudeep Pharma Share Price
1099.40-7.80 (-0.70%)
+42.01% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Sudeep Pharma Share Price
1099.40-7.80 (-0.70%)
+42.01% past 1 Year
News
Sudeep Pharma Reports Stronger Second Quarter EBITDA And Margin
Equity
SUDEEPPHRM
Sudeep Pharma Reports Stronger Second Quarter Consolidated Net Profit
Equity
SUDEEPPHRM
Sudeep Pharma Reports Strong Second Quarter Revenue Growth
Equity
SUDEEPPHRM
Sudeep Pharma Receives FDA Approval For New Gujarat Manufacturing Facility
Equity
SUDEEPPHRM
Sudeep Pharma flags steady state asset turns for battery and greenfield facilities
Equity
SUDEEPPHRM
Sudeep Pharma outlines strategy to meet FY27 growth objectives via expansion
Equity
SUDEEPPHRM
Sudeep Pharma sustains 30 percent profit growth outlook post greenfield expansion
Equity
SUDEEPPHRM
Sudeep Pharma greenfield PFN facility expected to commission in Q3
Equity
SUDEEPPHRM
Sudeep Pharma plans major capacity expansion to 200 KTPA by FY30-31
Equity
SUDEEPPHRM
Sudeep Pharma targets Phase 1 commissioning of SAM project by April 2027
Equity
SUDEEPPHRM
Sudeep Pharma outlines gradual recovery plan for NSS overseas subsidiary margins
Equity
SUDEEPPHRM
Sudeep Pharma expects specialty ingredients growth to normalise from Q2 FY27
Equity
SUDEEPPHRM
Sudeep Pharma reiterates EBITDA margin guidance range for overall business
Equity
SUDEEPPHRM
Sudeep Pharma expects Q1 FY27 momentum to continue into Q2
Equity
SUDEEPPHRM
Sudeep Pharma Q1 EBITDA rises year-on-year despite slight margin compression
Equity
SUDEEPPHRM
Sudeep Pharma Q1 revenue rises year-on-year to Rs 158 crores
Equity
SUDEEPPHRM
Sudeep Pharma Q1 consolidated net profit rises sharply year-on-year
Equity
SUDEEPPHRM
Sudeep Pharma informs about press release
Equity
SUDEEPPHRM
Sudeep Pharma - Quaterly Results
Equity
SUDEEPPHRM
Sudeep Pharma plans major FY27 capacity expansion across key segments
Equity
SUDEEPPHRM